A month has gone by since the last earnings report for Johnson & Johnson (JNJ) . Shares have added about 13% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Johnson & Johnson due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Johnson & Johnson before we dive into how investors and analysts ...

Core Insights - AbbVie reported strong fourth-quarter and full-year 2025 results, surpassing expectations, primarily driven by its newer immunology drugs, Rinvoq and Skyrizi, which offset the decline of the legacy drug Humira [1] Financial Performance - Skyrizi and Rinvoq generated combined revenues of approximately $26 billion, reflecting over 40% year-over-year growth. Skyrizi sales increased by 50% year-over-year to $17.56 billion, while Rinvoq sales rose by 39% to $8.30 billion [2] - AbbVie anticipates overall sales to grow at a high single-digit revenue CAGR through 2029, with combined sales of Skyrizi and Rinvoq expected to exceed $31 billion in 2026, surpassing the long-term guidance of $31 billion for 2027 [4] Market Dynamics - The immunology market is experiencing strong growth, with significant market share gains for Skyrizi in psoriasis and Rinvoq in rheumatoid arthritis. New indications for both drugs, including recent approvals and potential future approvals, are expected to drive further growth [3][5] - AbbVie expects Rinvoq to secure approvals for vitiligo and alopecia areata in 2026, with additional phase III data anticipated for hidradenitis suppurativa and systemic lupus erythematosus [5] Competitive Landscape - AbbVie faces competition from Johnson & Johnson, which markets Stelara and Tremfya, and Eli Lilly, which recently received FDA approval for Omvoh in ulcerative colitis [7][8] Valuation and Estimates - AbbVie shares are currently trading at a P/E ratio of 15.14, below the industry average of 18.74, but above its five-year mean of 13.68 [12] - Estimate revisions for 2026 EPS have trended higher, while those for 2027 have decreased over the past 30 days [14]

经济观察网强生(JNJ.N)在2025年业绩超预期的背景下，股价于2026年2月12日收盘报244.55美元，单日 上涨1.53%，但未突破2025年12月创下的约250美元的历史高点。这一现象主要受以下因素影响： 业绩经营情况 强生2025年全年营收达941.93亿美元，同比增长6%，第四季度营收245.6亿美元，同比增长9.1%，均高 于市场预期。公司对2026年的营收指引为995亿至1005亿美元，调整后每股收益预期为11.43至11.63美 元，亦高于华尔街共识。尽管业绩稳健，但部分投资者可能已提前消化了利好，导致股价在历史高点附 近承压。 行业政策与环境 资金面与技术面 2月12日强生股价振幅达2.77%，成交额约25.1亿美元，显示多空分歧加剧。当日盘中最高触及246.35美 元，接近历史高点，但未能有效突破，部分原因可能源于技术性阻力位的抛压。同时，资金向防御性板 块倾斜的趋势虽支撑股价，但未能形成突破性动能。 综上，强生业绩虽超预期，但受行业分化、宏观压力及技术面因素制约，短期未突破历史新高。 以上内容基于公开资料整理，不构成投资建议。 2026年2月12日，美股三大指数集体下跌(道琼斯指数跌 ...

Core Viewpoint - Johnson & Johnson is positioned as a stable investment option amidst the volatility of high-growth AI stocks, with a notable 53% increase in share price over the past year, suggesting strong performance and potential for long-term income seekers [2][9]. Financial Performance - Johnson & Johnson's market capitalization stands at $575 billion, with a current share price of $238.32 and a dividend yield of 2.15% [7][5]. - The company has maintained a gross margin of 75.27%, indicating robust profitability [7]. Challenges and Risks - The company faces challenges such as government-led drug price negotiations affecting sales, particularly for certain medicines [4]. - Patent cliffs pose a risk, with the loss of exclusivity for the immunology drug Stelara leading to competition from biosimilars [4]. - Johnson & Johnson is also dealing with ongoing lawsuits related to its talc-based products, which could impact its reputation and financial standing [5]. Business Resilience - Johnson & Johnson's diverse portfolio across various therapeutic areas helps mitigate risks from competition and declining sales in specific products [7]. - The company is close to launching a robotic-assisted surgery device, which is expected to create additional growth opportunities [8]. - A strong balance sheet with the highest credit rating available positions the company well to navigate legal challenges and market fluctuations [8]. Dividend History - Johnson & Johnson is recognized as a "Dividend King," having increased its dividends for 63 consecutive years, making it an attractive option for income-focused investors [9].

Core Insights - Johnson & Johnson (JNJ) has a diverse revenue stream in its Innovative Medicine division, with sales reaching $60.4 billion in 2025, reflecting a 5.3% operational growth and a 4.1% organic growth despite the loss of exclusivity for Stelara [1][10] Group 1: Sales Performance - The Innovative Medicine segment achieved over $15 billion in sales for three consecutive quarters in 2025, marking the first time it surpassed $60 billion in full-year sales [2] - Key products such as Darzalex, Tremfya, and Erleada contributed significantly to growth, with Darzalex sales increasing by 23.0% to $14.35 billion, Erleada by 19.2% to $3.57 billion, and Tremfya by 40.5% to $5.2 billion [6][9] - The decline in Stelara sales by 41.3% to $6.08 billion in 2025 due to its loss of exclusivity negatively impacted the segment's growth by 1110 basis points [4][5] Group 2: Future Outlook - J&J anticipates accelerated growth in the Innovative Medicine segment in 2026, driven by key products and new launches, with expected growth of 5% to 7% from 2025 to 2030 [7][9] - The company expects a more pronounced impact from new products in 2026, including Rybrevant and Caplyta, following approvals in 2025 [7] - However, the impact of generic competition is expected to intensify in 2026, particularly for Stelara, Simponi, and Opsumit as they lose patent protection [8] Group 3: Competitive Landscape - J&J operates in key areas of immunology and oncology, facing competition from major drugmakers such as Novartis, AstraZeneca, AbbVie, and Amgen [10][11] Group 4: Stock Performance and Valuation - J&J's stock has outperformed the industry, rising 55.6% over the past year compared to an 18.0% increase in the industry [12] - The company's shares are currently trading at a price/earnings ratio of 20.63, higher than the industry average of 18.76 and above its five-year mean of 15.65 [14] - The Zacks Consensus Estimate for 2026 earnings has increased from $11.48 to $11.54, indicating positive sentiment [16]

AbbVie Financial Performance - AbbVie reported net revenue of $16.6 billion in Q4 2025, marking a 10% year-over-year increase, slightly exceeding analyst expectations, primarily driven by a strong performance from Humira [2][3] - Humira generated $1.2 billion in revenue during Q4, which was nearly 30% higher than Wall Street expectations, despite its overall decline due to generic competition [3] - For the full year 2025, AbbVie achieved net revenue of $61.2 billion, reflecting an 8.6% annual gain, with adjusted diluted earnings per share projected between $14.37 to $14.57 for 2026 [5] Product Performance Insights - Most of AbbVie's products met analyst estimates, except for Rinvoq, which fell short with quarterly revenue of nearly $2.4 billion, marking the second consecutive quarter of underperformance [3][4] - Skyrizi, another key product, had only a slight beat in performance, raising investor concerns about competition in the immunology market, particularly regarding Rinvoq and Skyrizi's prospects in the inflammatory bowel disease market [4] Market Challenges - The vaccine market is facing significant challenges due to a sudden shift in U.S. vaccine policy, increasing skepticism, and declining immunization rates, which threaten sales and future research in the sector [5]

Core Viewpoint - The article emphasizes the importance of dividend stocks as a reliable investment option, particularly during varying market conditions, highlighting three companies known as Dividend Kings that are recommended for long-term investment. Group 1: Dividend Kings Overview - Dividend Kings are companies that have increased their dividends for at least 50 consecutive years, indicating a strong commitment to returning value to shareholders [3]. - These companies provide passive income and can offer stability during market downturns while also benefiting from market upswings [2]. Group 2: Abbott Laboratories - Abbott Laboratories has a dividend of $2.52, yielding 2.4%, which is higher than the S&P 500's 1.1% yield [4]. - The company has a diversified healthcare business with four units: medical devices, diagnostics, nutrition, and established pharmaceuticals, providing security against downturns in any single unit [6]. Group 3: Target - Target has faced challenges recently, including a shift in consumer behavior and theft, but is implementing strategies to recover, such as creating an enterprise acceleration office [7][8]. - The company offers a dividend of $4.56, yielding 4.5%, which can provide passive income while the stock potentially rebounds [10]. Group 4: Johnson & Johnson - Johnson & Johnson spun off its consumer health business to focus on higher-growth areas, resulting in a 6% sales increase to over $94 billion last year and an 8% rise in adjusted diluted earnings per share [11][12]. - The company pays a dividend of $5.20, yielding 2.3%, making it a solid choice for passive income [14].

Core Insights - Johnson & Johnson is poised to achieve a significant milestone by potentially surpassing $100 billion in annual sales for the first time in its history in fiscal year 2026 [3][4] - The company reported a strong fourth-quarter performance for 2025, with sales increasing by 9.1% year over year to $24.6 billion and adjusted earnings per share rising by 20.6% to $2.46 [2] - Despite facing challenges such as the loss of patent exclusivity for key drugs and government price negotiations, Johnson & Johnson's diverse product lineup and robust pipeline support its consistent performance [7][8] Financial Performance - For fiscal year 2026, Johnson & Johnson projects sales between $100 billion and $101 billion, indicating a year-over-year revenue growth of 6.7% [4] - The company has a market capitalization of $548 billion, with a current stock price of $227.25 [5][6] - Johnson & Johnson maintains a gross margin of 75.27% and a dividend yield of 2.26%, highlighting its financial stability [6] Dividend Performance - Johnson & Johnson is recognized as a "Dividend King," having increased its dividend payouts for 63 consecutive years, making it an attractive option for dividend investors [9] - The company continues to sustain its dividend program despite facing patent expirations and price negotiations for some of its drugs [9]

Industry Overview - The pharmaceutical industry is facing a potential loss of $300 billion, which represents one-sixth of its overall revenue, by 2030 due to a patent cliff [1] - Companies that can adapt quickly will be better positioned to navigate this challenge [1] Company-Specific Insights - Eli Lilly and Novo Nordisk are well-positioned with limited patent exposure and significant earnings from GLP-1 weight loss drugs [2] - Bristol Myers Squibb faces a significant challenge with a projected growth gap of about $38 billion, primarily due to the loss of patent protection for its top drugs, Eliquis and Opdivo, which together account for over half of its earnings [3] - Merck & Co. and Pfizer are also facing substantial gaps of $23 billion and $21 billion, respectively [3] Strategic Responses - Successful companies are employing multi-faceted strategies to mitigate losses, including mergers and acquisitions (M&A) to strengthen their drug pipelines [4] - Beyond M&A, companies are also focusing on delaying patent expirations, exploring new drug development areas, and refocusing efforts to generate growth [5] Johnson & Johnson's Position - Johnson & Johnson is positioning itself as a success story amid the patent cliff, despite facing challenges such as biosimilar competition for its drug Stelara, which could lead to a $15 million revenue gap [6] - The company’s drug Darzalex, with projected sales of almost $18 billion in 2024, will soon encounter its own patent cliff [6] - J&J reported over $24 billion in quarterly sales with a 6% increase in annual sales, surpassing market expectations, and is framing 2025 as a pivotal year for growth [7]

Core Insights - Johnson & Johnson (JNJ) is recognized as a Dividend King, having consistently paid and increased dividends for over 50 years, making it a stable investment option during market volatility [1] - JNJ stock outperformed the market with a 43.7% increase last year, compared to the market's overall gain of 16.6%, and has continued to rise by over 10% in early 2026 [2] Business Structure and Performance - In 2023, JNJ spun off its consumer division into a separate company called Kenvue (KVUE), allowing JNJ to focus on a pure-play health care innovation business centered on drugs and medical devices [4] - The Innovative Medicine segment is the primary revenue driver, generating $15.7 billion in Q4 2023, a 10% year-over-year increase, and $60.4 billion for the full year, reflecting a 6% increase [4] - JNJ reported a 5.3% increase in worldwide sales to $94.2 billion, despite challenges from the loss of exclusivity on Stelara, with adjusted diluted earnings per share rising 8.1% to $10.79 [4] Growth Prospects - Oncology is projected to achieve 21% operational sales growth in 2025, with anticipated annual sales exceeding $50 billion by 2030, marking it as a significant growth engine for the company [5] - The MedTech segment also showed strong performance, with a 7.5% revenue growth in Q4 and 6.1% for the full year, generating $34 billion in sales, driven by advancements in Cardiovascular, Surgery, and Vision [5] - JNJ's MedTech division is supported by over 60 active clinical trials and multiple regulatory submissions planned, positioning it as a key growth pillar alongside Pharmaceuticals [5][6]